Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
larger decrease » marked decrease (Expand Search)
lower decrease » linear decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
based based » based case (Expand Search), based basis (Expand Search), ranked based (Expand Search)
Showing 1 - 20 results of 198,828 for search '(( significant based based ) OR ( significantly ((lower decrease) OR (larger decrease)) ))', query time: 1.52s Refine Results
  1. 1
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 2
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 3
    Significant associations in GWAS.

    Significant associations in GWAS. by Dai Nogimura (21445649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 5
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 6
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 7
    Comparison of upper and lower arch crowding between premolar extraction group and the mandibular third molar extraction groups.

    Comparison of upper and lower arch crowding between premolar extraction group and the mandibular third molar extraction groups. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    eQTL analysis of significant SNPs.

    eQTL analysis of significant SNPs. by Dai Nogimura (21445649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Significant associations in the candidate gene approach.

    Significant associations in the candidate gene approach. by Dai Nogimura (21445649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    County-level geographical septile distribution for the first 12 statistically significant factors with at least one statistically significant coefficient ranked by decreasing ΔIC.

    County-level geographical septile distribution for the first 12 statistically significant factors with at least one statistically significant coefficient ranked by decreasing ΔIC. by Yanan Long (11784717)

    Published 2021
    Save to List
    Saved in:
  11. 11
    Raw data used to calculate the statistical significances stated in the result section.

    Raw data used to calculate the statistical significances stated in the result section. by Tom Adriaenssens (397863)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 12
    Suggestive significant associations in the candidate gene approach.

    Suggestive significant associations in the candidate gene approach. by Dai Nogimura (21445649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 14
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 15
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 16
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 17
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 18
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 19
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 20
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: